The Atlas Study

Currently Recruiting

29 Jun 2026

Up to $5,800

Brisbane, Australia

Chronic kidney disease (CKD) is a long-term condition where the kidneys slowly lose their ability to work properly. One of the main reasons this happens is something called fibrosis, which is basically scarring inside the kidneys. Over time, this scarring makes the kidneys stiff and less able to filter waste from the blood. Current treatments mostly help with symptoms or try to slow the damage, but they don’t stop the scarring itself. 

The study drug being tested is different. It’s designed to go after the root cause of the problem, the scarring process. In the body, there are certain signals that tell tissues to form scar tissue. These signals keep the scarring going and make the kidneys worse over time. The potential new drug blocks both signals at the same time. By doing this, it aims to stop the scarring from getting worse and might even help reverse some of the damage. 

If this works, it could be a big step forward because it’s not just managing symptoms tackling the actual process that causes kidney failure. That means people with CKD could keep their kidneys working longer and avoid serious complications. This is a new approach that researchers hope will fill a big gap in current treatment options. 

Apply now Speak with us 1300 113 766

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions. 

What to expect?

  • Participation in a monitored clinical environment 
  • Study visits scheduled  
  • Support from a professional medical team 
  • Reimbursement for your time and commitment 

Trial details

Study duration

  • 2 screening visits
  • 2 night stay
  • 8 follow-up visits

Additional eligibility

  • Weigh between 50kg and 100kg for males
  • Weigh between 45 and 100kg for females
  • Not taking any medications within 14  days of admission (as advised by our medical team)
  • Non-smokers or smoking less than 5 cigarettes per week
  • Not pregnant or breastfeeding
  • Willing to follow contraception guidelines (If applicable)
  • Willing and able to attend all study visits and follow instructions

Study medication

Administered as an intravenous (IV) infusion

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $5,800 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

BMI

BMI 17.5 - 32 kg/m2

Commitment

2 nights, 8 clinic visits

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact